What about the SSMs? To test if vaccine had 'primed' the dLN SSMs we synchronously immunised the ndLN with an irrelevant non-cognate antigen. Now when we boost the 'ndLN' with cognate antigen there was larger recall & more GCs, just like dLN! This effect was abolished by anti-CSF1R mAb blocking. - ThreadSky

About ThreadSky

labphan.bsky.social • 36 days ago

What about the SSMs? To test if vaccine had 'primed' the dLN SSMs we synchronously immunised the ndLN with an irrelevant non-cognate antigen. Now when we boost the 'ndLN' with cognate antigen there was larger recall & more GCs, just like dLN! This effect was abolished by anti-CSF1R mAb blocking.

Comments

labphan.bsky.social•36 days ago

This was all done in inbred genetically modified mice using intravital microscopy. Could boosting the same versus opposite side make a difference in 'wildtype' 'outbred' humans? This is where the Kirby Institute team came into their own! In the clinical study they also sampled the LN by FNB!

labphan.bsky.social•36 days ago

Please note caveats about persistent GCs from the COVID mRNA vaccine (Turner, Ellebedy et al. Nature 2021). Regardless, we did see more GCs in the boosted dLN compared to ndLN

labphan.bsky.social•36 days ago

This was associated with more rapid secretion of neutralising antibodies against the ancestral strain in the vaccine as well as Delta and Omicron variants. In agreement, there was more somatic hypermutation & antibody diversification in the boosted dLN compared to ndLN.

labphan.bsky.social•36 days ago

So location does matter & boosting on the same side may make a difference! Basic research can underpin clinical translation. Can't have one without the other! Thankful to all our funders especially NHMRC, ACRF & UNSW Scientia Program. Thank you for reading please check out our paper! End 🧵

Posting Rules

Be respectful to others
No spam or self-promotion
Stay on topic
Follow Bluesky's terms of service

Comments

Posting Rules

Reply